News

MicroAire Completes Acquisition of NEOSYAD

MicroAire Surgical Instruments, the global leader in power-assisted liposuction, is pleased to announce the acquisition of NEOSYAD, an innovative medical device company that developed a breakthrough technology for adipose tissue engineering. This strategic move reinforces MicroAire’s commitment to advancing medical innovation and strengthening its leadership in the adipose tissue market.

NEOSYAD recently received EU MDR approval for their AdiMate® device and Adipure® single-use kit. Thanks to its patented “all-in-one” concept and integrated proprietary software, AdiMate optimizes operating times by combining the infiltration, liposuction, and adipose tissue preparation (lipofilling) functions. The protocol integrated in the machine allows tissue purification in less than 10 minutes in a completely automatic way, while guaranteeing unmatched adipose tissue quality and viability.

Strengthening MicroAire’s Adipose Tissue Leadership

MicroAire’s PAL® handpiece is the #1 power-assisted liposuction device in the United States and a global leader among plastic surgeons. The acquisition of NEOSYAD marks a significant step forward in MicroAire’s vision to strengthen its leadership in the global adipose tissue market. Jerome Barrillon, President of MicroAire, shared his enthusiasm for the partnership: “We are thrilled to welcome the NEOSYAD team into the MicroAire family. Their expertise, innovative products, and dedication to advancing adipose tissue technologies perfectly align with our mission to enable better patient outcomes and support plastic surgeons worldwide.”

Barrillon further emphasized the strategic fit: “NEOSYAD’s advanced adipose tissue technology complements MicroAire’s existing portfolio and will help us accelerate our vision of expanding our leadership in the adipose tissue market. Together, we are poised to deliver unparalleled value to our customers and drive innovation in this growing field.”

Regis Roche, NEOSYAD’s co-founder and President, commented: “We are delighted to join forces with MicroAire, a company that shares our commitment to innovation and excellence in adipose tissue processing. This partnership represents a unique opportunity to scale our groundbreaking solutions and bring the benefits of AdiMate and Adipure to a broader global audience.”

Roche continued: “Our technology has already demonstrated excellent results in enhancing outcomes for patients, particularly in breast reconstruction procedures. By ensuring a higher quality of purified fat and significantly reducing operating times, we enable surgeons to perform procedures with greater precision and efficiency. Together with MicroAire, we aim to make these advanced solutions more accessible to patients worldwide, offering them a safer, more effective option for restoring their confidence and well-being.”

 

Read more here.

Recent News

02/05/2025

Project Vital bringing millions in funding to Roanoke-Blacksburg’s life sciences

The Roanoke-Blacksburg region is establishing itself as a biomedical research hub and medical device innovation center. About $5 million from the state could help move that work from labs to markets. Those millions will fund Project Vital: Virginia Innovations and Technology Advancements in Life Sciences. It’s a collaboration among the Roanoke-Blacksburg Innovation Alliance (formerly Verge),

01/31/2025

AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated

01/30/2025

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who